(Q43527880)

English

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

arterial hypertension

1 reference

based on heuristic

inferred from title

Marius M Hoeper

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

7

object named as

Marc Humbert

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

3

object named as

David G Kiely

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

Maurice Beghetti

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Joern Carlsen

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Barbara Schwierin

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Eleanor S Segal

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

0 references

publication date

1 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Pediatric Research

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

200-204

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

https://scigraph.springernature.com/pub.10.1203/pdr.0b013e318179954c

0 references

Cellular and molecular pathobiology of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Pulmonary arterial hypertension in children

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Outcomes in children with idiopathic pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Epoprostenol treatment in children with severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Vasodilator therapy for primary pulmonary hypertension in children

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Survival with first-line bosentan in patients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Effects of long-term bosentan in children with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Response to bosentan in children with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Primary pulmonary hypertension in childhood

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Pharmacoepidemiology: current status, prospects, and problems

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318179954C

21 January 2018

Identifiers

10.1203/PDR.0B013E318179954C

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43527880&oldid=2098118985"